LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release fourth-quarter and full-year 2023 financial results on Thursday, Feb. 22, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Conference Call Details
|
Date: |
Thursday, Feb. 22, 2024 |
|
Time: |
8:00 a.m. U.S. EST |
|
Webcast: |
A replay of the conference call will be available on the investor relations website.
To participate in the live Q&A session, please register using this link to receive a PIN, which will be sent an hour before the conference call.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
| Investor Contact: | Media Contact: |
| ir@bauschhealth.com | Kevin Wiggins |
| (877) 281-6642 (toll-free) | corporate.communications@bauschhealth.com |
| (908) 541-3785 |
SOURCE: Bausch Health Companies Inc.
View the original press release on accesswire.com
Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition…
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader…
Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or…
Parexel also launching a comprehensive Radiopharmaceuticals report at the meeting Onsite Parexel experts include recently…
Lantern also announces clinical team and partner expansion to deliver accelerated treatmentDALLAS, May 29, 2025…
IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
